NCT04262024View on ClinicalTrials.gov

Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia.

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

January 5, 2023

Study Completion Date

May 1, 2023

Conditions
Health Education
Interventions
DRUG

cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education

Women with hyperprolactiemia scheduled for cabergoline therapy 1.5-2 mg/week). for one month will be offered health education to help minimize prolactin level(group A)

DRUG

cabergoline 1.5-2 mg/week).orally daily for 1 month without health education

Women with hyperprolactiemia scheduled for cabergoline 1.5-2 mg/week).for one month will not be offered health education (group B)

Trial Locations (1)

71111

Woman's Health University Hospital, Asyut

All Listed Sponsors
lead

Woman's Health University Hospital, Egypt

OTHER

NCT04262024 - Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia. | Biotech Hunter | Biotech Hunter